143 related articles for article (PubMed ID: 32128760)
1. A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites.
Turner RM; Fontana V; Zhang JE; Carr D; Yin P; FitzGerald R; Morris AP; Pirmohamed M
Clin Pharmacol Ther; 2020 Aug; 108(2):287-297. PubMed ID: 32128760
[TBL] [Abstract][Full Text] [Related]
2. Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.
Mykkänen AJH; Tarkiainen EK; Taskinen S; Neuvonen M; Paile-Hyvärinen M; Lilius TO; Tapaninen T; Klein K; Schwab M; Backman JT; Tornio A; Niemi M
Clin Pharmacol Ther; 2024 Jun; 115(6):1428-1440. PubMed ID: 38493369
[TBL] [Abstract][Full Text] [Related]
3. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
Ramakumari N; Indumathi B; Katkam SK; Kutala VK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
Hoste E; Haufroid V; Deldicque L; Balligand JL; Elens L
Clin Biochem; 2024 Feb; 124():110707. PubMed ID: 38182100
[TBL] [Abstract][Full Text] [Related]
5. The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.
León-Cachón RBR; Bamford AD; Meester I; Barrera-Saldaña HA; Gómez-Silva M; Bustos MFG
Sci Rep; 2020 Jun; 10(1):8900. PubMed ID: 32483134
[TBL] [Abstract][Full Text] [Related]
6. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
Linskey DW; English JD; Perry DA; Ochs-Balcom HM; Ma C; Isackson PJ; Vladutiu GD; Luzum JA
Pharmacogenet Genomics; 2020 Dec; 30(9):208-211. PubMed ID: 32453264
[TBL] [Abstract][Full Text] [Related]
7. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
Lu B; Sun L; Seraydarian M; Hoffmann TJ; Medina MW; Risch N; Iribarren C; Krauss RM; Oni-Orisan A
Clin Pharmacol Ther; 2021 Sep; 110(3):733-740. PubMed ID: 34114646
[TBL] [Abstract][Full Text] [Related]
8. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.
Liu JE; Liu XY; Chen S; Zhang Y; Cai LY; Yang M; Lai WH; Ren B; Zhong SL
Eur J Clin Pharmacol; 2017 Nov; 73(11):1409-1416. PubMed ID: 28812116
[TBL] [Abstract][Full Text] [Related]
9. Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.
Carr DF; Francis B; Jorgensen AL; Zhang E; Chinoy H; Heckbert SR; Bis JC; Brody JA; Floyd JS; Psaty BM; Molokhia M; Lapeyre-Mestre M; Conforti A; Alfirevic A; van Staa T; Pirmohamed M
Clin Pharmacol Ther; 2019 Dec; 106(6):1353-1361. PubMed ID: 31220337
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose.
Cestari RN; Rocha A; Marques MP; de Oliveira RDR; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121766. PubMed ID: 31450089
[TBL] [Abstract][Full Text] [Related]
11. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS.
Dheyaa Aziz N; Abbood SH; Al-Mayali AH; Hadi NR
Pol Merkur Lekarski; 2023; 51(5):496-503. PubMed ID: 38069850
[TBL] [Abstract][Full Text] [Related]
12. Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention.
Turner RM; Fontana V; FitzGerald R; Morris AP; Pirmohamed M
Br J Clin Pharmacol; 2020 Jan; 86(1):62-74. PubMed ID: 31656041
[TBL] [Abstract][Full Text] [Related]
13. Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.
Bakar NS; Neely D; Avery P; Brown C; Daly AK; Kamali F
Clin Pharmacol Ther; 2018 Jul; 104(1):178-187. PubMed ID: 28940218
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
15. The effect of
Wang Y; Tian Y; Lv P; Chen L; Luo W; Jing X; Li H; Tan Z; Wang Y; Zhou H; Ouyang DS
Pharmazie; 2017 Jun; 72(6):365-368. PubMed ID: 29442027
[TBL] [Abstract][Full Text] [Related]
16. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
17. Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin.
Cestari RN; de Oliveira RDR; de Souza FFL; Pippa LF; Nardotto GHB; Rocha A; Donadi EA; Lanchote VL
Clin Transl Sci; 2020 Nov; 13(6):1227-1235. PubMed ID: 32463566
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
El-Zailik A; Cheung LK; Wang Y; Sherman V; Chow DS
J Pharm Biomed Anal; 2019 Feb; 164():258-267. PubMed ID: 30396053
[TBL] [Abstract][Full Text] [Related]
19. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Xiang Q; Chen SQ; Ma LY; Hu K; Zhang Z; Mu GY; Xie QF; Zhang XD; Cui YM
Pharmacogenomics J; 2018 Dec; 18(6):721-729. PubMed ID: 30250148
[TBL] [Abstract][Full Text] [Related]
20. Statin-associated muscle symptoms in coronary patients: design of a randomized study.
Munkhaugen J; Vethe NT; Fagerland MW; Dammen T; Perk J; Gjertsen E; Otterstad JE; Gullestad L; Bergan S; Husebye E
Scand Cardiovasc J; 2019 Jun; 53(3):162-168. PubMed ID: 31030568
[No Abstract] [Full Text] [Related]
[Next] [New Search]
